Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Nkarta, Inc. NASDAQ:NKTX | $195.68M | $2.74 | Not rated | -2.0 | -37.43% |
Alector, Inc. NASDAQ:ALEC | $174.86M | $1.58 | Not rated | -1.4 | +88.52% |
Molecular Partners AG NASDAQ:MOLN | $148.22M | $3.95 | Not rated | -2.0 | -38.90% |
Spero Therapeutics, Inc. NASDAQ:SPRO | $129.13M | $2.23 | Undervalued | 8.2 | -63.28% |
PepGen Inc. NASDAQ:PEPG | $120.70M | $1.75 | Not rated | -1.6 | -28.93% |
Vor Biopharma Inc. NASDAQ:VOR | $103.52M | $15.10 | Not rated | -0.0 | +136.83% |
Elicio Therapeutics, Inc. NASDAQ:ELTX | $71.95M | $3.77 | Not rated | -1.7 | -66.67% |
Seres Therapeutics, Inc. NASDAQ:MCRB | $62.56M | $6.46 | Overvalued | -1.3 | -81.56% |
Continue the stock analysis
Jump to another research area for this company.